Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation

Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation

Background Although many studies have defined mechanisms of resistance to EGFR‐TKIs, acquired resistance remains the major limitation of monotherapy with EGFR‐TKIs. Methods Cell viability was analyzed using a Cell Counting Kit‐8 (CCK‐8) assay. EGFR T790M mutation was sequenced on a HiSeq 4000 platfo...

Full description

Bibliographic Details
Main Authors: Zengzhi Lian, Wenwen Du, Yang Zhang, Yulong Fu, Ting Liu, Anqi Wang, Tingting Cai, Jianjie Zhu, Yuanyuan Zeng, Zeyi Liu, Jian‐an Huang
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Thoracic Cancer
Subjects:
Anlotinib
EGFR‐TKI
FGFR1
non‐small cell lung cancer
resistance
Online Access:https://doi.org/10.1111/1759-7714.13485

Internet

https://doi.org/10.1111/1759-7714.13485

Similar Items